Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Clinical trial NCT05002816 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05002816
- Sponsor
- Yale University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-21
- Primary completion
- 2026-01-22
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.